CNR2
ENSG00000188822
Target class
GPCR
Chromosome
1
Approved drugs
0
Clinical candidates (approved and in development)
8
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- Yes
- Other names
- CB2
- Target name
- CNR2
- Gene name
- Cannabinoid receptor 2
- Gene symbol
- CNR2
- Protein name
- Cannabinoid receptor 2 (CB-2) (CB2) (hCB2) (CX5)
- Gene biotype
- Protein coding
- Gene family
- Cannabinoid receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 4
- Highest tissue expression
- 16.58
- Tissue specificity (Gini)
- 0.937
- Tissue specificity (tau)
- 0.98
- KEGG gene identifiers
- hsa:1269
- Protein interaction confidence
- 0.8564
- Protein interaction partners
- 10
- R-HSA-373076
- R-HSA-418594
- End position
- 23913362
- Start position
- 23870515
- Chromosome
- 1
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein. Cell projection, dendrite . Perikaryon . Note=Localizes to apical dendrite of pyramidal neurons. .
- Tissue specificity (tau)
- 0.980153
- Expression inequality (Gini)
- 0.936878
Expression in transcripts per million
- Spleen
- 16.58
- Cells - EBV-transformed lymphocytes
- 12.43
- Small Intestine - Terminal Ileum
- 2.08
- Whole Blood
- 1.24
- Thyroid
- 0.38
Expression in transcripts per million
- Spleen16.58
- Cells - EBV-transformed lymphocytes12.43
- Small Intestine - Terminal Ileum2.08
- Whole Blood1.24
- Thyroid0.38
- Testis0.26
- Lung0.15
- Colon - Transverse0.09
- Esophagus - Mucosa0.07
- Liver0.06
- Prostate0.04
- Fallopian Tube0.04
- Adipose - Visceral (Omentum)0.04
- Kidney - Medulla0.03
- Cervix - Endocervix0.03
- Stomach0.03
- Cervix - Ectocervix0.03
- Kidney - Cortex0.03
- Artery - Coronary0.03
- Bladder0.03
- Artery - Aorta0.03
- Adipose - Subcutaneous0.02
- Vagina0.02
- Pituitary0.02
- Minor Salivary Gland0.02
And 29 more, listed on the interactive page.
- GO:0038171
- GO:0045669
- GO:0005783
- GO:0005886
- GO:0004949
- GO:0005515
decreased inflammation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased inflammation
- nervous system
- Immune
PubMed 28216264increased inflammation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased inflammation
- nervous system
- Immune
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- Immune
PubMed 28216264
increased inflammation
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased inflammation
Biological samples
- Immune
PubMed 23197038decreased bone mass
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased bone mass
Biological samples
- Immune
PubMed 23197038
Related records
Trials (270)
- A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking
- A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients
- A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
- A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
- A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting
- A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas
- A Pilot Trial of Nabilone for the Treatment of Obesity
- A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
- A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis
- A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty
- A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
- A Study of GW842166 in Adults With Osteoarthritis Pain
- A Study of LY2828360 in Patients With Osteoarthritic Knee Pain
- A Study of MK0364 in Obese Patients (0364-014)
- A Study Of Synthetic THC And Sleep
- A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users
- A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis
- A Study Testing the Safety and Effects of Single Doses of S1-221 in Healthy Volunteers
- A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)
- A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Drugs (17)
- Beta-caryophyllene
- Dronabinol
- GW842166X Cannabinoid CB2 receptor agonist
- Ibipinabant
- Lenabasum
- LY2828360 Cannabinoid CB2 receptor agonist
- Nabilone
- Nonabine Cannabinoid CB2 receptor agonist
- Olorinab Cannabinoid CB2 receptor agonist
- Onternabez
- PRS-211375 Cannabinoid CB2 receptor agonist
- S-777469 Cannabinoid CB2 receptor agonist
- SAD448 Cannabinoid CB2 receptor agonist
- Surinabant
- Taranabant
- Tedalinab Cannabinoid CB2 receptor agonist
- Vicasinabin